LTRN
Lantern Pharma Inc.
Price Chart
Latest Quote
$3.95
+0.12 (+3.13%)
Current Price
| Previous Close | $3.83 |
| Open | $3.80 |
| Day High | $4.03 |
| Day Low | $3.80 |
| Volume | 296,215 |
Stock Information
| Shares Outstanding | 12.76M |
| Total Debt | $59K |
| Cash Equivalents | $6.32M |
| Net Income | $-15.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $50.40M |
| EPS (TTM) | $-1.45 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $38.39M |
| Income | $-15.91M |
| Book/sh | $0.31 |
| Cash/sh | $0.50 |
| Employees | 16 |
Financial Ratios
| Quick Ratio | 1.67 |
| Current Ratio | 1.87 |
| Debt/Eq | 1.71 |
Returns & Margins
| ROA | -73.31% |
| ROE | -157.37% |
Ownership
| Insider Ownership | 17.15% |
| Institutional Ownership | 14.16% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.96 |
| P/B | 12.91 |
Analyst Data
| Recommendation | none |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $3.75 |
| SMA50 | $3.03 |
| SMA200 | $3.23 |
| RSI | 63.41 |
| ATR | 0.3617 |
| Shares Float | 9.59M |
| Short Float | 11.62% |
| Short Ratio | 4.84 |
| Rel Volume | 1.38 |
Performance History
| Week | +1.02% |
| Month | +12.86% |
| Quarter | +77.13% |
| 6 Months | +21.17% |
| YTD | +27.01% |
| Year | +28.66% |
| 3 Years | -34.28% |
| 5 Years | -73.70% |
| 10 Years | -73.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $3.95 | 296,200 |
| 2026-06-23 | $3.83 | 58,500 |
| 2026-06-22 | $3.88 | 104,300 |
| 2026-06-18 | $3.79 | 209,000 |
| 2026-06-17 | $3.89 | 257,800 |
| 2026-06-16 | $3.91 | 214,300 |
| 2026-06-15 | $3.69 | 197,500 |
| 2026-06-12 | $3.88 | 133,000 |
| 2026-06-11 | $4.07 | 155,900 |
| 2026-06-10 | $3.88 | 152,300 |
| 2026-06-09 | $3.81 | 287,700 |
| 2026-06-08 | $3.75 | 379,500 |
| 2026-06-05 | $3.59 | 249,400 |
| 2026-06-04 | $3.79 | 358,300 |
| 2026-06-03 | $3.40 | 192,100 |
| 2026-06-02 | $3.74 | 253,700 |
| 2026-06-01 | $3.74 | 198,200 |
| 2026-05-29 | $3.59 | 116,000 |
| 2026-05-28 | $3.50 | 323,400 |
| 2026-05-27 | $3.31 | 148,200 |
| 2026-05-26 | $3.38 | 224,100 |
About Lantern Pharma Inc.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
đ° Latest News
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
Motley Fool âĸ 2026-05-21T14:39:34Z
Promising Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-15T12:05:13Z
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga âĸ 2026-05-13T17:06:16Z
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
GuruFocus.com âĸ 2026-04-03T01:00:57ZLantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Insider Monkey âĸ 2026-02-12T16:19:29Z
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely
Simply Wall St. âĸ 2025-11-15T12:20:14Z
FDA clears Starlight Therapeuticsâ IND for Phase Ib/IIa glioblastoma trial
Clinical Trials Arena âĸ 2025-08-07T09:34:00Z
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
Clinical Trials Arena âĸ 2025-08-01T09:45:37Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $17,978,494 | $22,216,437 | $17,877,570 | $14,432,753 |
| Other Income Expense | $421,125 | $692,869 | $1,150,648 | $-31,548 |
| Other Non Operating Income Expenses | $421,125 | $692,869 | $1,150,648 | $-31,548 |
| Net Non Operating Interest Income Expense | $437,931 | $742,355 | $765,388 | $204,355 |
| Operating Expense | $17,978,494 | $22,216,437 | $17,877,570 | $14,432,753 |
| General And Administrative Expense | $6,464,371 | $6,090,747 | $5,983,255 | $5,829,799 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Net Interest Income | $437,931 | $742,355 | $765,388 | $204,355 |
| Interest Income | $437,931 | $742,355 | $765,388 | $204,355 |
| Normalized Income | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Net Income From Continuing And Discontinued Operation | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Total Operating Income As Reported | $-17,978,494 | $-22,216,437 | $-17,877,570 | $-14,432,753 |
| Net Income Common Stockholders | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Net Income | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Net Income Including Noncontrolling Interests | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Net Income Continuous Operations | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Pretax Income | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Interest Income Non Operating | $437,931 | $742,355 | $765,388 | $204,355 |
| Operating Income | $-17,978,494 | $-22,216,437 | $-17,877,570 | $-14,432,753 |
| Per Share | ||||
| Diluted EPS | $-1.57 | $-1.93 | $-1.47 | $-1.31 |
| Basic EPS | $-1.57 | $-1.93 | $-1.47 | $-1.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-17,961,214 | $-22,199,155 | $-17,862,955 | $-14,422,672 |
| Reconciled Depreciation | $17,280 | $17,282 | $14,615 | $10,081 |
| EBITDA (Bullshit earnings) | $-17,961,214 | $-22,199,155 | $-17,862,955 | $-14,422,672 |
| EBIT | $-17,978,494 | $-22,216,437 | $-17,877,570 | $-14,432,753 |
| Diluted Average Shares | $10,898,175 | $10,762,319 | $10,842,365 | $10,850,579 |
| Basic Average Shares | $10,898,175 | $10,762,319 | $10,842,365 | $10,850,579 |
| Diluted NI Availto Com Stockholders | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Research And Development | $11,514,123 | $16,125,690 | $11,894,315 | $8,602,954 |
| Selling General And Administration | $6,464,371 | $6,090,747 | $5,983,255 | $5,829,799 |
| Other Gand A | $6,464,371 | $6,090,747 | $5,983,255 | $5,829,799 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Total Assets | $11,035,811 | $25,571,792 | $43,647,616 | $58,836,321 |
| Total Non Current Assets | $232,639 | $324,163 | $306,291 | $113,584 |
| Other Non Current Assets | $36,738 | $36,738 | $25,869 | $17,889 |
| Non Current Deferred Assets | $88,431 | $0 | - | - |
| Current Assets | $10,803,172 | $25,247,629 | $43,341,325 | $58,722,737 |
| Other Current Assets | $683,948 | $1,234,566 | $2,038,653 | $2,985,472 |
| Cash Cash Equivalents And Short Term Investments | $10,119,224 | $24,013,063 | $41,302,672 | $55,196,085 |
| Cash And Cash Equivalents | $4,422,838 | $7,511,079 | $21,937,749 | $37,201,786 |
| Cash Equivalents | $1,539,533 | $6,619,476 | $20,881,000 | $1,271,000 |
| Cash Financial | $2,883,305 | $891,603 | $1,056,749 | $35,930,786 |
| Restricted Cash | - | - | $0 | $541,180 |
| Prepaid Assets | - | - | - | $2,985,472 |
| Debt | ||||
| Total Debt | $78,539 | $243,657 | $234,471 | $52,890 |
| Long Term Debt And Capital Lease Obligation | $0 | $52,843 | $61,496 | $0 |
| Current Debt And Capital Lease Obligation | $78,539 | $190,814 | $172,975 | $52,890 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,501,587 | $4,384,018 | $2,739,682 | $2,798,297 |
| Total Non Current Liabilities Net Minority Interest | $0 | $52,843 | $61,496 | $0 |
| Current Liabilities | $4,501,587 | $4,331,175 | $2,678,186 | $2,798,297 |
| Payables And Accrued Expenses | $4,423,048 | $4,140,361 | $2,505,211 | $2,745,407 |
| Equity | ||||
| Common Stock Equity | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Total Equity Gross Minority Interest | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Stockholders Equity | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Gains Losses Not Affecting Retained Earnings | $25,430 | $153,990 | $-107,460 | $-371,386 |
| Other Equity Adjustments | $25,430 | $153,990 | $-107,460 | $-371,386 |
| Retained Earnings | $-93,145,055 | $-76,025,617 | $-55,244,404 | $-39,282,870 |
| Other | ||||
| Ordinary Shares Number | $11,254,697 | $10,784,725 | $10,721,192 | $10,857,040 |
| Share Issued | $11,254,697 | $10,784,725 | $10,721,192 | $10,857,040 |
| Tangible Book Value | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Invested Capital | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Working Capital | $6,301,585 | $20,916,454 | $40,663,139 | $55,924,440 |
| Capital Lease Obligations | $78,539 | $243,657 | $234,471 | $52,890 |
| Total Capitalization | $6,534,224 | $21,187,774 | $40,907,934 | $56,038,024 |
| Additional Paid In Capital | $99,652,724 | $97,058,323 | $96,258,726 | $95,691,194 |
| Capital Stock | $1,125 | $1,078 | $1,072 | $1,086 |
| Common Stock | $1,125 | $1,078 | $1,072 | $1,086 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $52,843 | $61,496 | $0 |
| Current Capital Lease Obligation | $78,539 | $190,814 | $172,975 | $52,890 |
| Net PPE | $107,470 | $287,425 | $280,422 | $95,695 |
| Gross PPE | $107,470 | $287,425 | $280,422 | $95,695 |
| Other Properties | $107,470 | $287,425 | $280,422 | $95,695 |
| Other Short Term Investments | $5,696,386 | $16,501,984 | $19,364,923 | $17,994,299 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,678,695 | $-17,825,796 | $-14,365,282 | $-12,795,336 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,676,980 | $-17,813,201 | $-14,346,548 | $-12,767,492 |
| Cash Flow From Continuing Operating Activities | $-15,676,980 | $-17,813,201 | $-14,346,548 | $-12,767,492 |
| Operating Gains Losses | $84,540 | $210,664 | $127,340 | $187,520 |
| Investing Activities | ||||
| Capital Expenditure | $-1,715 | $-12,595 | $-18,734 | $-27,844 |
| Investing Cash Flow | $11,057,073 | $3,369,368 | $-930,210 | $179,268 |
| Cash Flow From Continuing Investing Activities | $11,057,073 | $3,369,368 | $-930,210 | $179,268 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,624,547 | $0 | - | $0 |
| Financing Cash Flow | $1,498,240 | $66,710 | $-499,997 | $-2,182,498 |
| Cash Flow From Continuing Financing Activities | $1,498,240 | $66,710 | $-499,997 | $-2,182,498 |
| Net Other Financing Charges | $-139,749 | - | $-499,997 | - |
| Net Common Stock Issuance | $1,624,547 | $0 | $-499,997 | $-2,482,286 |
| Common Stock Issuance | $1,624,547 | $0 | - | $0 |
| Repurchase Of Capital Stock | - | - | $-499,997 | $-2,482,286 |
| Net Preferred Stock Issuance | - | - | - | $-2,482,286 |
| Other | ||||
| End Cash Position | $4,422,838 | $7,511,079 | $21,937,749 | $37,742,966 |
| Beginning Cash Position | $7,511,079 | $21,937,749 | $37,742,966 | $52,524,295 |
| Effect Of Exchange Rate Changes | $33,426 | $-49,547 | $-28,462 | $-10,607 |
| Changes In Cash | $-3,121,667 | $-14,377,123 | $-15,776,755 | $-14,770,722 |
| Proceeds From Stock Option Exercised | $13,442 | $66,710 | $0 | $299,788 |
| Net Investment Purchase And Sale | $11,058,788 | $3,381,963 | $-911,476 | $207,112 |
| Sale Of Investment | $25,780,771 | $20,657,643 | $7,284,667 | $4,119,682 |
| Purchase Of Investment | $-14,721,983 | $-17,275,680 | $-8,196,143 | $-3,912,570 |
| Net PPE Purchase And Sale | $-1,715 | $-12,595 | $-18,734 | $-27,844 |
| Purchase Of PPE | $-1,715 | $-12,595 | $-18,734 | $-27,844 |
| Change In Working Capital | $635,278 | $2,228,160 | $538,024 | $-611,863 |
| Change In Other Current Liabilities | $-190,625 | $-175,715 | $-159,255 | $-158,402 |
| Change In Other Current Assets | $0 | $-10,869 | $-7,980 | $0 |
| Change In Payables And Accrued Expense | $271,808 | $1,636,440 | $-236,181 | $580,359 |
| Change In Prepaid Assets | $554,095 | $778,304 | $941,440 | $-1,033,820 |
| Other Non Cash Items | $556,797 | $173,211 | $160,228 | $144,600 |
| Stock Based Compensation | $650,877 | $732,893 | $1,067,515 | $1,187,745 |
| Unrealized Gain Loss On Investment Securities | $-305,887 | $-155,624 | $-119,650 | $492,501 |
| Amortization Of Securities | $-196,427 | $-238,574 | $-173,086 | $81,870 |
| Depreciation Amortization Depletion | $17,280 | $17,282 | $14,615 | $10,081 |
| Depreciation And Amortization | $17,280 | $17,282 | $14,615 | $10,081 |
| Gain Loss On Investment Securities | $242,505 | $-9,065 | $115,840 | $128,922 |
| Net Foreign Currency Exchange Gain Loss | $-157,965 | $219,729 | $11,500 | $58,598 |
| Net Income From Continuing Operations | $-17,119,438 | $-20,781,213 | $-15,961,534 | $-14,259,946 |
| Common Stock Payments | - | - | $-499,997 | $-2,482,286 |
| Preferred Stock Payments | - | - | - | $-2,482,286 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-22